Real-World Data Drives CAR T Treatment Decisions
Payers and providers use real-world data to identify high-performing treatment centers and support value-based contracting arrangements.
In 2017, the first two CAR T-cell therapies, Kymriah and Yescarta, were approved, transforming blood cancer treatment.
Since then, these therapies have been approved for additional indications and five new CAR T-cell therapies have been introduced.
As the CAR T pipeline expands, the current infrastructure may struggle to meet increased demand.
Real-world data reveals benefits of earlier CAR T administration.
Author's summary: Real-world data informs CAR T treatment decisions.
More News
- Gartner Identifies the Top Strategic Technology Trends for
- Elaine Hendrix on Vegan Living, ‘Dancing With the Stars’, and Life After ‘The Parent Trap’
- Windows File Explorer Previews are Vulnerable to NTLM Hash Leakage – How to Stay Safe - Make Tech Easier
- The importance of competency in uncertain times
- Pre-school praised for 'working hard to improve' with exemplary Ofsted report